EMEA-000576-PIP02-11-M04

Key facts

Active substance	Tofacitinib
Therapeutic area	Dermatology
Decision number	P/0055/2017
PIP number	EMEA-000576-PIP02-11-M04
Pharmaceutical form(s)	Film-coated tablet Oral solution
Condition(s) / indication(s)	Treatment of psoriasis
Route(s) of administration	Oral use
Contact for public enquiries	Pfizer Limited United Kingdom Tel. +44 (0)1304 646 607 Fax +44 (0)1304 657 750 E-mail: pip_enquiries@pfizer.com
Decision type	PM: decision on the application for modification of an agreed PIP

Decision

List item

P/0055/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA- 000576-PIP02-11-M04) (PDF/75.87 KB)

Adopted

First published: 20/04/2017
Last updated: 20/04/2017
EMA/104672/2017

Related documents

List item

Tofacitinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision (PDF/82.35 KB) (new)

First published: 27/09/2023
EMEA-000576-PIP02-11-M04

How useful was this page?

Add your rating

★ ★ ★ ★ ★